Switch to oxymorphone cost saving for chronic pain
- PDF / 141,812 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 5 Downloads / 174 Views
tment scenario: Scenario 1 Scenario 2 Scenario 3
QD
BID
TID
2368 2635 2775
4299 5073 5098
6230 7750 7422
The cost contribution of immediate-release treatment to the total expected cost for treatment scenarios 1, 2 and 3 would be 17%, 21% and 24%, respectively. Magar RS, et al. Expected cost and cost considerations associated with opioid rotation for chronic non-cancer pain: a simulation model. Value in Health 10: 801084961 A464 (plus poster) abstr. PPN3, No. 6, Nov-Dec 2007
1173-5503/10/0541-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 17 Nov 2007 No. 541
1
Data Loading...
